Benign prostatic hyperplasia (BPH) is a common condition among aging men, often leading to lower urinary tract symptoms (LUTS) of varying severity. Both medical and surgical treatments for BPH can negatively impact sexual function, affecting patients' overall quality of life. This has highlighted the need for minimally invasive interventions that minimize sexual side effects. Rezum, a water vapor therapy, has gained popularity in managing BPH and LUTS due to its proposed potential to preserve sexual function. This scoping review examines the impact of Rezum therapy on sexual function in patients treated for BPH. The review was conducted following the Joanna Briggs Institute (JBI) methodology for scoping reviews. A comprehensive search was performed using the PubMed and Scopus databases up to August 2024. Articles were included if they involved patients treated with Rezum for BPH and reported the effect of Rezum on sexual function using validated scoring tools. A total of 15 studies encompassing 2,425 patients, met the inclusion criteria. Erectile function was assessed in all studies using the International Index of Erectile Function (IIEF) scores. Of these, seven studies reported no significant changes in erectile function scores, six demonstrated improvements, and two reported a significant decline. Ejaculatory function was evaluated using the Male Sexual Health Questionnaire (MSHQ). The MSHQ‐Bother score was reported in seven studies, with three indicating improvement and none reporting deterioration. The MSHQ‐Function score was reported in eight studies, with only one study reporting a decline, while the remaining studies found no significant changes. In conclusion, Rezum therapy for managing BPH shows favorable outcomes for sexual function or, at the very least, does not negatively impact it. These findings can guide patient counseling, especially for those seeking to preserve ejaculation. Further research is needed to compare Rezum with other treatment options regarding sexual function.